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Abstract 
The exploitation of hot melt extrusion and injection molding for the manufacturing of immediate 
release (IR) tablets was preliminarily investigated in view of their special suitability for 
continuous manufacturing, which represents a current goal of pharmaceutical production because 
of its possible advantages in terms of improved sustainability. 
Tablet-forming agents were initially screened based on processability by single-screw extruder 
and micromolding machine as well as disintegration/dissolution behavior of extruded/molded 
prototypes. Various polymers, such as low-viscosity hydroxypropylcellulose, polyvinyl alcohol, 
polyvinyl alcohol-polyethylene glycol graft copolymer, various sodium starch glycolate grades 
(e.g. Explotab® CLV) that could be processed with no need for technological aids, except for a 
plasticizer, were identified. Furthermore, the feasibility of both extruded and molded IR tablets 
from low-viscosity hydroxypropylcellulose or Explotab® CLV was assessed. Explotab® CLV, in 
particular, showed thermoplastic properties and a very good aptitude as a tablet-forming agent, 
starting from which disintegrating tablets were successfully obtained by either techniques. 
Prototypes containing a poorly soluble model drug (furosemide), based on both a simple 
formulation (Explotab® CLV and water/glycerol as plasticizers) and formulations including 
dissolution/disintegration adjuvants (soluble and effervescent excipients) were shown to fulfill 
the USP 37 dissolution requirements for furosemide tablets. 
 
 
 
Keywords: tablet, extrusion, formulation, oral drug delivery, polymers, continuous 
manufacturing, injection molding; Explotab® CLV; Nisso HPC SSL.  
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1. INTRODUCTION 
The pharmaceutical industry is considered one of the most dedicated to innovation, as the total 
expenditure on research and development over US $ 100 billion could confirm.1 However, only 
marginal attempts at improving the manufacturing efficiency have been reported, even though 
this has been highlighted as a very promising area of interest, especially with respect to the 
sustainability of dosage form development and manufacturing.2 Traditionally, medicines have 
always been manufactured through a batch method, in which materials are charged before the 
start of the process and discharged at the end. The final dosage form is obtained stage by stage 
over a series of workstations. This approach has been exploited for decades and it allows all 
regulatory requirements to be fulfilled. However, it does not offer adequate flexibility in 
responding to demand changes. As a consequence, in the last ten years the interest in the 
potential application of continuous manufacturing (CM) to the pharmaceutical field has been 
growing.3-6 CM consists in producing/processing, without interruption, materials generally 
maintained in motion and undergoing chemical reactions or mechanical/heating treatments. 
Nowadays, this method is largely used in oil refining and production of paper as well as 
chemicals, where “continuous” commonly means operating 24 hours per day, 7 days per week 
with infrequent maintenance shutdowns, such as semi-annual or annual. According to the Food 
and Drug Administration (FDA), continuous processing has the potential for improving product 
quality and the industry is encouraged to truly consider a shift in this direction. Moreover, such a 
method was shown to be consistent with the FDA’s efforts towards quality by design 
implementation. Advantages related to CM are undeniable. It could reduce the time and costs of 
development simply by avoiding the moving of materials among facilities, limiting the stored 
amount of hazardous chemicals thus improving sustainability, overcoming the need for stopping, 
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re-configuration and testing between batches as well as that for scaling up. In fact, transfer from 
pilot-plant to full-production scale could be accomplished by just increasing the process time or 
making more lines work in parallel. Thanks to the restrained dimensions of the equipment 
required, a further increase of process efficiency could be achieved through a better exploitation 
of the manufacturing area. Although many examples of continuous pharmaceutical processes that 
are run in a batch mode (e.g. blending, granulation, drying, tableting) have been reported,7-12 the 
first end-to-end (i.e. from drug synthesis to dosage form production) integrated CM plant was 
only very recently proposed.13-15 Such a plant involves the flow of components through different 
individual units, where all the conditions/parameters are clearly defined and controlled. A 
prototype immediate release (IR) tablet was achieved by extruding and injecting a basic 
thermoplastic formulation, composed of an in situ synthesized model drug and polyethylene 
glycol (PEG), into a properly shaped mold. 
Hot-processing techniques, such as hot melt extrusion (HME) and injection molding (IM), would 
especially be suitable for fulfilling the needs of CM. Such techniques are widely employed 
within the plastics industry for large-scale production also of precision components. While the 
former is exploited to create items having a fixed, and in some cases complex, cross-sectional 
profile, the latter allows objects with a well-defined three dimensional shape to be manufactured. 
Over the last two decades HME and IM have found several applications in the pharmaceutical 
field, in particular for the manufacturing of modified-release drug products.16,17 Egalet®, for 
instance, is a prolonged- and pulsatile-release delivery platform at an advanced development 
stage, which is obtained by double-injection molding. On the other hand, melt extruded 
formulations for prolonged release, intended either for oral administration or as inserts/implants, 
are currently on the market (e.g. Isoptin-SRE® and Nuvaring®). Moreover, HME has 
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successfully been applied to enhance the dissolution rate/bioavailability of drugs by promoting 
the formation of solid dispersions with thermoplastic carriers, and, again, a few products reached 
the marketplace (e.g. Kaletra® and Gris-PEG®).18 With respect to IR dosage forms, starch-based 
injection-molded shells (Capill®) were proposed as an alternative to dip-molded gelatin 
capsules.17 Furthermore, powders or granules derived from milling of extruded dispersions may 
be compressed to give IR tablets.16 HME and IM are also mentioned by Eur. Pharm. 8.019, along 
with compression, as suitable techniques for the manufacturing of directly-shaped tablets. 
However, only a preliminary research paper published in the late ‘90s has preceded the one 
relevant to the integrated CM plant in describing the use of IM for the manufacturing of IR 
tablets within one single production step.20 In these instances, polyethylene glycol (PEG) was 
considered as the sole thermoplastic vehicle without any broadening of the formulation study. As 
regards extruded products, it is only in very recent times that the dissolution performance of 
directly-shaped units has been taken into account.21,22 Therefore, the use of hot-processing 
techniques for the production of IR tablets still needs to be explored. In particular, an attentive 
formulation set-up is required to offset the poor porosity that is typical of extruded/molded items 
and may impair a prompt drug dissolution. The use of these manufacturing techniques would 
also result in the possibility of carrying out solvent-free processes, overcoming mixing and/or 
compaction issues, patenting the obtained products and enhancing the relevant versatility in 
terms of size/shape. Because IR tablets represent the top-selling dosage form in the 
pharmaceutical market, their CM would indeed be a remarkable accomplishment and could open 
the way for many other products. 
Based on these premises, the aim of the present work was the evaluation of polymeric 
components and the identification of formulation strategies for the achievement, by HME and 
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IM, of solid units having acceptable IR characteristics (high disintegration/dissolution rate), thus 
strengthening the use of these innovative techniques and ultimately supporting progress in CM 
within the pharmaceutical field. 
 
2. MATERIALS AND METHODS 
2.1 Materials 
Hydroxypropyl cellulose (HPC; Nisso SSL, Nisso, Tokyo, Japan); hydroxypropyl methyl 
cellulose (HPMC; Methocel® E5, Colorcon, West Point, Pennsylvania); polyvinyl alcohol (PVA; 
Gohsenol®, Nippon Goshei, Hull, United Kingdom); polyvinyl alcohol-polyethylene glycol graft 
copolymer (KIR; Kollicoat® IR, BASF, Düsseldorf, Germany); polyvinyl caprolactam-polyvinyl 
acetate-polyethylene glycol graft co-polymer (Soluplus®, BASF, Düsseldorf, Germany); 
metacrylic acid copolymer (Eudragit® E PO, Evonik, Darmstadt, Germany); corn starch 
(Ingredion, Westchester, Illinois); sodium starch glycolates (EXP, Explotab®; EXPCLV, 
Explotab® CLV; VIV, Vivastar®; JRS Pharma, Rosenberg, Germany); vinylpyrrolidone-vinyl 
acetate copolymer (KVA; Kollidon® VA 64, BASF, Düsseldorf, Germany); deionized water 
(W); glycerol (GLY; Pharmagel, Lodi, Italy), polyethylene glycols (PEG; 400, 1500, 6000 and 
8000, Clariant Masterbatches, Milan, Italy); talc (Carlo Erba, Milan, Italy); croscaramellose 
sodium (AcdiSol®, FMC BioPolymer, Philadelphia, Pennsylvania); low-substituted 
hydroxypropyl cellulose (L-HPC, ShinEtsu, Tokyo, Japan); sodium chloride (NaCl, Carlo Erba, 
Milan, Italy); sodium hydrogen carbonate (NaHCO3, Carlo Erba, Milan, Italy); calcium 
carbonate (CaCO3, Carlo Erba, Milan, Italy); citric acid (Carlo Erba, Milan, Italy); tartaric acid 
(Carlo Erba, Milan, Italy); furosemide (Metapharmaceutical, Barcelona, Spain). 
 
2.2 Methods 
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2.2.1 CHARACTERIZATION OF MATERIALS 
Hot-plate experiment 
2-3 g samples of polymer/polymeric formulation were placed in an aluminum pan on a hot plate 
and heated under continuous manual mixing, while gradually increasing the temperature up to 
200 °C. Samples were checked for overall aspect, color, texture and mechanical characteristics 
during heating and after cooling. 
Air shot test 
50 g samples of polymer/polymeric formulation were loaded into the IM press through the 
hopper and expelled from the injecting unit as during a purge operation.23 The test was repeated 
under different operating temperatures. Samples were checked for overall aspect, color and 
mechanical characteristics immediately after ejection and after cooling. 
X-Ray diffraction 
X-ray diffractograms were collected with a X'pert Pro MPD diffractometer (Panalytical, 
Westborough, Massachusetts), using Cu-Kα radiation (λ=1.5418 Å). The generator voltage and 
current were set at 45 kV and 40 mA, respectively and the 2-theta scanning range was from 4 to 
40° (step size 0.0083556°, scan speed 0.053907°/s). Powder samples and extruded/molded 
samples of uniform thickness were analyzed. 
 
2.2.2 MANUFACTURING OF EXTRUDED AND MOLDED UNITS 
Tablet-forming polymers, except for PEGs, were kept in a ventilated oven at 40 °C for 24 h prior 
to use. Plasticized polymeric formulations were prepared by mixing or granulating polymers in a 
mortar with the selected solid or liquid plasticizer, respectively; the amount of plasticizer was 
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expressed as weight % (wt%) on the dry polymer. Adjuvants and/or drug were added to 
plasticized formulations by mixing in a mortar; the amount of the added component was 
expressed as wt% on the final formulation. As far as starch and starch derivatives are concerned, 
final formulations to be processed by IM were prepared by extrusion through a 4 mm rod-shaped 
die (see HME process). Only for the EXPCLV-based formulations containing effervescent 
adjuvants, the latter were added after extrusion, in order to limit their early contact with water 
and exposure to high temperatures. 
HME process 
HME was carried out by a single-screw extruder (Extrusiograph 19/25D, Brabender, Duisburg, 
Germany) equipped with rod-shaped (diameter 4 or 8 mm) or ribbon-shaped (thickness 1 mm) 
dies. Process parameters (barrel T1-T2-T3 and die T4 temperatures, screw rate) and torque values 
were recorded. Rods of 4 mm in diameter were manually cut into pellets and then processed by 
IM; rods of 8 mm in diameter rods were cut into tablets (thickness 4 mm) by a bench-top saw. 
Rods of 30 mm in diameter disks were die-cut from extruded sheets.  
IM process 
IM was performed by a bench-top micromolding machine (BabyPlast 6/10P, Cronoplast S.L.; 
Rambaldi S.r.l., Lecco, Italy). Materials were loaded through the hopper into the plasticating 
chamber of the IM press by means of the loading plunger and then conveyed to the injecting 
chamber. By successively applying two distinct pressures, the injection pressure P1 (maintained 
for 2.5 sec) and the holding pressure P2 (maintained for 1.5 sec), both at a selected rate (r1 and r2, 
respectively) expressed as a percentage of the maximum one, a second plasticating plunger (10 
mm diameter) moved 7-16 mm forward thus injecting specific amounts of formulation through a 
1 mm nozzle into the mold cavity. Molded items were prepared by way of two different molds: 
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(i) a disk-shaped mold of 30 mm in diameter and 1 mm in thickness provided with a central gate; 
(ii) a cylindrical mold of 8 mm in diameter and 4 mm in height provided with a central gate. 
Prior to product ejection, the mold was kept closed (2.5-15 sec at 15 °C) and the formulation was 
allowed to cool and harden. The disk-shaped mold was manually lubricated with vegetable oil 
approximately every 20 manufactured units; the first disk obtained after this operation was 
discarded. 
 
2.2.3 CHARACTERIZATION OF EXTRUDED AND MOLDED UNITS 
HME and IM units were checked for weight (analytical balance BP211, Sartorius, Elk Grove, 
Illinois; n = 10) and thickness (digimatic indicator ID-C112X, Mitutoyo, Milan, Italy; n = 10). 
Digital photographs (Nikon D70, Nikon, Milan, Italy) and photomicrographs (SEM; Sigma, 
Zeiss, Munich, Germany; gold sputtering, 10 nm) of tablets not exposed to the aqueous medium 
and withdrawn at different times during the mass loss test were acquired; samples dried in a 
ventilated oven at 40 °C for 24 h were evaluated. 
Mass loss test 
The mass loss test on extruded and molded placebo units (disks and tablets) (n = 3) was carried 
out in both a USP37 dissolution apparatus (apparatus 2, Dissolution System Distek Inc. 2000, 
North Brunswick Township, New Jersey; 1000 mL of distilled water or 1M HCl solution, 37 ± 
0.5 °C, 100 rpm) and in a six-position disintegration apparatus (800 mL of distilled water or HCl 
1M, 37 ± 0.5 °C, 31 cycles/min). Samples to be tested by dissolution apparatus were inserted into 
a polyethylene net (5 mm mesh for disks and 2 mm mesh for tablets). Tablets to be tested by 
disintegration apparatus were each inserted into a single basket-rack assembly. At pre-
determined times samples were withdrawn and oven-dried (40 °C) to constant weight. 
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Percentage mass loss was calculated with respect to the initial sample weight. Times to 10 and 
80 % mass loss (t10 and t80, respectively) were obtained from mass loss data and the difference 
between the two values (t80-10) indicated mass loss rate. 
Dissolution test 
The drug dissolution test (n = 3) was performed by USP37 apparatus 2 (Dissolution System 
Distek Inc. 2000, North Brunswick Township, New Jersey) under the following operating 
conditions: 900 mL of pH 5.8 phosphate buffer, 37 ± 0.5 °C, 50 rpm.24 Fluid samples were 
withdrawn at fixed times and assayed spectrophotometrically (274 nm). At the end of the test (90 
min), the total amount of drug dissolved was determined after vortex mixing (10 min). The 
percentage of furosemide dissolved at each times was calculated with respect to the final 
dissolved amount. Dissolution parameters were statistically compared by umpired 2-tail t-student 
test, accounting for heteroscedasticity. The differences were considering significant with p < 
0.05. 
 
3. RESULTS AND DISCUSSION 
HME and IM are well established processing techniques in the plastics industry. Despite the 
number of applications proposed in the scientific literature and some products already on the 
market, there is still much work to be done before they may be widely exploited for the 
preparation of directly-shaped IR tablets. In this respect, the first objective of the present work 
was the identification of pharma-grade polymers suitable for being processed and able to lead to 
products having the desired performance. Such polymers should not be considered merely as 
conventional fillers because they represent the thermoplastic components essential to the 
achievement of the final dosage form, i.e. the tablet-forming agents. The dissolution of the active 
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ingredient should start as soon as IR formulations come in contact with biological fluids, and the 
dissolution rate should primarily depend on the physical-chemical properties of the drug while 
not being limited by the dosage form characteristics. 25 In this respect, HME and IM products 
may be critical because of a generally higher bulk density and lower porosity with respect to 
compressed ones of analogous composition (e.g. prolonged-release matrix systems, 
implants).12,26,27 A screening of traditional fillers, either soluble or insoluble, known for their 
thermoplastic properties and already proposed for hot-processing, was therefore undertaken. 
 
3.1. Screening of tablet-forming agents 
The possibility of using polymers as tablet-forming agents in HME and IM would depend on the 
processing temperatures and the rheological properties of the melt as well as the 
thermal/mechanical stability of the obtained products that has a great impact on the versatility of 
tablets in terms of shape, dimensions and drug loads. In this respect, based on the need for the 
material to be extruded/injected through thin gaps, which involves higher shear stresses, sheets 
and disk prototypes were employed in order to discriminate the behavior of different polymers. 
Soluble polymers used as carriers for solid dispersions prepared by HME (HPC, HPMC, PVA, 
KIR, KVA, Soluplus, Eudragit E) and thermoplastic starch were initially considered.28-38 Also 
polyethylene glycols (PEG 6000 and 8000), which were the only polymers already proposed for 
the manufacturing of tablets by IM, were taken into account for comparison purposes.20 In 
addition, the ability of starch derivatives employed as disintegrants for solid dosage forms (EXP, 
EXPCLV, VIV) to behave like thermoplastic starch does when processed in the same way, i.e. in 
admixture with plasticizers, under thermal and mechanical stresses, and to maintain 
hydration/swelling properties, was investigated. 
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As a preliminary step, hot-plate and air shot tests were performed to determine or confirm the 
working temperatures of the selected polymers and assess whether plasticizers were needed or 
not.39-40 The choice of the type and amount of plasticizer as well as the identification of 
parameters to be used for the evaluation of HME and IM processability, were then accomplished 
through the preparation of extruded sheets (1 mm in thickness) and molded disk-shaped 
prototypes (1 mm in thickness and 30 mm in diameter), respectively (table 1). The HME 
processability of materials under investigation was evaluated based on morphological 
(uniformity of shape and thickness) and mechanical characteristics of extruded sheets. On the 
other hand, IM processability was rated according to the aspect (integrity and thickness) and 
mechanical characteristics of the molded disks as well as the possibility of their automatic 
ejection at the end of a molding cycle, thus providing a continuous manufacturing process. 
A series of promising tablet-forming agents was identified that could be processed by HME and 
IM with no need for technological aids, except for plasticizers that both decreased the working 
temperatures and counteracted the glassy nature of the extruded/molded products. In this respect, 
hot-processing techniques would involve a remarkably limited number of excipients as compared 
with traditional tablet manufacturing by compression. PEGs only could be processed as such. 
However, they were characterized by very low melting points and viscosities at their working 
temperatures, which impaired the achievement of extruded sheets or any other item with inherent 
consistency. By IM, PEG products could be obtained because this technique envisages cooling 
and hardening inside a mold, nevertheless their original shape was not maintained over time. 
Some difficulties were also encountered in processing HPMC and Eudragit E by HME as well as 
KVA by both the techniques, although these may be overcome when changing equipment and/or 
shape/size characteristics of items produced. 
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As far as the starch derivatives are concerned, they became extrudable under thermal and 
mechanical stresses in the presence of water/glycerol mixtures, as already observed with starch. 
However, the amount of plasticizer and the rate of extrusion needed to be increased in order to 
process the starch derivatives. The relevant extruded products showed a marked and durable loss 
of crystallinity. By way of example, X-ray profiles of EXPCLV-based samples immediately after 
extrusion and following six-months storage at ambient conditions (24 ± 2 °C, 55 ± 5 % RH) are 
reported in figure 1. It can be noticed that retrogradation or post-crystallization phenomena, 
typical of thermoplastic starch, did not occur in the case of sodium starch glycolate, at least 
within the considered period of storage.30 
Disk-shaped prototypes, obtained by cutting the extruded sheets or by molding, were used to 
study the behavior of the polymeric formulations when in contact with aqueous fluids. 
Parameters calculated from their mass loss profiles are reported in table 2. 
Most of the samples lost at least 10 % of the initial mass (t10diss) in less than 10 min, in most 
cases within 5 min, and a further 70 % (t80-10diss) within about 60 min. Mass loss could be 
attributed to dissolution phenomena, predominant, as expected, in the case of samples based on 
soluble polymers, and mechanical erosion. The detachment of macroscopic fragments from the 
external surface of disks was evident with starch-derived disintegrants only. Differences between 
the mass loss performance of HME and IM disks with the same composition were not observed 
in spite of possibly different porosities. When present, such differences may fail to be 
highlighted owing to non-properly discriminating test conditions. Indeed, because disks were 
inserted into a polyethylene net, the access of water might be restricted and hydration/swelling 
phenomena, generally leading to the disintegration of solids, might consequently be limited. 
Moreover, fragments larger than the mesh size (> 5 mm) were not able to escape through the net, 
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thus not being accounted as mass loss. Such issues were overcome when dealing with tablet 
products. 
 
3.2. Placebo tablets 
Two of the polymeric formulations that showed a good balance between HME/IM processability 
and fast mass loss performance, but a different dissolution/disintegration behavior, were selected 
for the manufacturing of tablets. HME and IM processes for the preparation of extrudates of 8 
mm in diameter, subsequently cut into cylindrical items of 4 mm in thickness (i.e. final HME 
tablets), and molded tablets of the same size, respectively, based on HPC and EXPCLV were set 
up (formulations 1a and 2a in table 3). The manufacturing of placebo tablets, i.e. based on 
thermoplastic tablet-forming agents only, turned out to be less critical with respect to that of 
disks. In particular, IM tablets were obtained with no need for lubrication. 
In order to better discriminate between the performance of differently prepared tablets, the mass 
loss test was carried out by both dissolution apparatus, with tablets inserted into a polyethylene 
net of 2 mm mesh, and disintegration apparatus, with tablets freely moving in the basket-rack 
assembly (figure 2). 
The mass loss rate of HME tablets turned out to be higher with respect to IM ones, irrespective 
of composition and test conditions. This could be due to possibly different surface and density 
characteristics of the products. Upon injection under high pressure into the mold cavity, in fact, a 
tight packing of polymer chains and a sudden cooling at the mold surface would take place, 
which may overall account for poor solvent penetration into the final item.27,41 When tested by 
disintegration apparatus, all tablets except for the molded ones based on HPC showed an 
increase in mass loss over time. The mass loss increase was more evident with those materials 
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which are known to possess an intrinsic ability to promote disintegration (EXPCLV vs HPC) or 
when tablet density could be assumed to be lower (extruded vs molded tablets). The different 
behavior of EXPCLV and HPC formulations when exposed to the aqueous fluid was confirmed by 
the aspect of the tablets recovered. By way of example, in figure 3 photographs of the molded 
tablets and photomicrographs of their surface, before and after exposure to the aqueous medium 
for different periods of time, are reported. 
In the SEM images relevant to EXPCLV-based tablets, cracks can be seen, already after 5 min of 
exposure to aqueous fluids, which could be attributed to the detachment of fragments. On the 
contrary, the surface of HPC tablets appears unchanged. Such findings are consistent with 
hypothesized mass loss mechanisms based on mechanical erosion or dissolution. This was 
confirmed by photographs of samples at successive times (10-60 min in the dissolution 
apparatus), which pointed out a progressive reduction in volume of the HPC tablets without any 
notable change in their shape, thus supporting the occurrence of dissolution phenomena. On the 
other hand, it was evident that EXPCLV tablets underwent a process of deaggregation. 
 
3.3. Drug containing tablets 
In order to further evaluate the potential for immediate release of the thermoplastic tablet-
forming agents, a model drug, challenging in terms of dissolution properties, was selected. 
Tablets containing 20 % of furosemide42 (class IV of the Biopharmaceutics Classification 
System; Tm = 206 °C) were prepared by both HME and IM. Process conditions and dissolution 
profiles are reported in table 3 (formulations 1l and 2l) and figure 4, respectively. 
Dissolution results from furosemide-containing tablets were in agreement with mass loss from 
placebo ones. In fact, drug dissolution rate turned out higher in the case of extruded tablets and 
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EXPCLV-based formulations as compared with molded and HPC-based ones, respectively. The 
HPC-based formulations gave rise to non-disintegrating matrices from which drug liberation 
would occur through the swollen polymer. On the contrary, thermoplastic EXPCLV was 
confirmed to be a very promising filler that would enable the manufacturing of disintegrating 
tablets by the investigated hot-processing techniques. Indeed, extruded prototypes having the 
simplest formulation (i.e. polymer/plasticizer/drug) fulfilled the requirements of USP 37 for IR 
furosemide tablets (i.e. not less than 80 % of furosemide dissolved in 60 min).24 
The use of dissolution/disintegration adjuvants was also attempted in order to enhance the rate of 
drug liberation. The possibility of adding soluble (NaCl, KIR), effervescent (NaHCO3, CaCO3, 
citric and tartaric acids) and disintegrant (AcdiSol, L-HPC) excipients to HPC and EXPCLV 
formulations was investigated.27,40,43-45 
All tablets, either placebo or containing the drug, were successfully prepared after minimal 
adjustments of process parameters (table 3). Only a few HME manufacturing processes relevant 
to placebo formulations containing citric acid or tartaric acid and CaCO3, in admixture with 
NaHCO3 (formulations 1e, 1f, 1m and 2e), failed because of the difficulty of coping with 
excessive shear forces. When tablets containing effervescent excipients were successfully 
prepared, an internal porous structure was observed, especially in the case of HPC-based molded 
samples (figure 5). This could be attributed to the evolution of CO2 gas resulting from the 
thermal decomposition of sodium bicarbonate in the softened polymer.44 
Dissolution parameters, i.e. the percentages of furosemide dissolved after 20 and 60 min (%20min 
and %60min, respectively), relevant to adjuvant-containing tablets and reference products based on 
HPC and EXPCLV only are reported in table 4. 
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Adjuvants that were able to increase the mass loss of HPC tablets (data not shown) generally 
improved the furosemide liberation, mainly from IM products. In particular, the best 
performance was obtained with the molded tablets containing NaHCO3 and tartaric acid (> eight-
fold amount of furosemide dissolved after 60 min as compared with 1a reference formulation). 
Indeed, these tablets not only showed a porous network but also a residual effervescent activity 
when in contact with the aqueous fluids, which could account for improved dissolution. A 
different behavior was observed in the case of formulations containing disintegrants. While mass 
loss of placebo products was increased by the latter adjuvants, AcdiSol® slightly improved the 
dissolution rate of furosemide from molded tablets only. Moreover, the disintegrant did not 
significantly affect (p > 0.05) drug dissolution parameters of HME units. 
EXPCLV was confirmed an advantageous filler for the preparation of IR tablets by HME and IM. 
Indeed, three relevant formulations, one of which was obtained by HME and the other two by 
IM, fulfilled USP requirements for furosemide tablets.24 In particular, when taking into account 
the contribution of the adjuvants to the improvement of disintegration and dissolution rate, 
effervescent excipients turned out to be more effective in molded rather than extruded tablets. 
During IM processing, wherein exposure to high temperatures is of shorter duration, thermal 
decomposition of sodium bicarbonate and resulting CO2 evolution would less likely occur. 
Accordingly, a residual effervescence ability might have been maintained thus aiding the 
disintegration of tablets in contact with aqueous fluids. The addition of the soluble adjuvant KIR 
resulted in enhanced drug dissolution rate, and this effect was comparable with, or in the case of 
HME tablets even better than, that of effervescent-containing products. Unlike all other EXPCLV-
based tablets, neither placebo nor drug-loaded KIR-containing ones gave rise to visible residues 
after the relevant exposure to aqueous fluids. Such a behavior was considered worth being 
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further investigated. Finally, in the presence of AcdiSol®, the rate of furosemide dissolution from 
both extruded and molded EXPCLV-based products was decreased. The ability of the disintegrant 
to promote mass loss of placebo units in aqueous medium was thus not reflected in an enhanced 
drug dissolution rate. This already occurred with HME HPC-based tablets containing the same 
adjuvant. In this respect, the presence of salts in the buffer medium might account for a lower 
amount of water available for the hydration/swelling of EXPCLV and/or AcdiSol
®. Indeed, the 
dissolution rate of furosemide increased when the test was performed under the mass loss 
experimental conditions, i.e. water instead of phosphate buffer as the medium, and 100 instead of 
50 rpm: %20min 21.32 (CV 1.89) and %60min 69.16 (CV 3.36) for HME EXPCLV-based tablets; 
%20min 40.20 (CV 3.81) and %60min 92.63 (CV 1.21) for IM EXPCLV-based tablets. 
 
4. CONCLUSIONS 
The possibility of manufacturing tablets with potential for IR by HME and IM techniques, which 
could advantageously fulfill the needs of CM, may help progress of this emerging production 
mode in the pharmaceutical industry. Accordingly, a broad screening of pharmaceutical grade 
polymers was carried out aimed at evaluating the relevant suitability as tablet forming agents. 
Their selection was based on the polymer processability by both techniques and the 
disintegration/dissolution aptitude of the extruded/molded items obtained. The dissolution 
performance of extruded and molded tablets containing the poorly-soluble drug furosemide as a 
challenging tracer molecule was also investigated. 
It was possible to identify a variety of suitable soluble and insoluble tablet-forming agents, able 
to give rise to consistent IR tablets starting from simple formulations, in some cases based on the 
polymer and plasticizer only, and showing appropriate behavior in aqueous medium. Sodium 
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starch glycolate (i.e. Explotab®, Explotab® CLV and Vivastar®), in particular, was demonstrated 
to be processable as a thermoplastic polymer and led to items with an intrinsic tendency towards 
disintegration that was rather unexpected in view of the low inherent porosity of 
extruded/molded products. Moreover, formulation strategies based on the use of soluble, 
disintegrant and effervescent adjuvants to promote tablet disintegration and drug dissolution 
were successfully set up. Explotab® CLV-based units with different composition, prepared by 
both HME and IM, turned out to comply with USP dissolution requirements for furosemide thus 
pointing out an interesting application potential of these techniques for the production of IR 
tablets, which may ultimately be exploited for continuous manufacturing. 
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Figure 1: X-ray profiles of powdered Explotab
®
 CLV and polymer-based sheets immediately after 
extrusion and after 6 months storage. 
 
Figure 2: mass loss profiles of the HPC- and EXPCLV-based tablets performed in the dissolution (a) or 
disintegration (b) equipment. 
 
Figure 3: Digital photographs and photomicrographs of molded placebo tablets based on HPC and 
EXPCLV, before and after exposure to the aqueous medium. Digital photographs are referred to units 
tested in the dissolution apparatus. 
 
Figure 4: Dissolution profiles of HPC- and EXPCLV-based tablets containing furosemide. 
 
Figure 5: Photomicrographs of (a) HPC- and (b) EXPCLV-based placebo molded tablets containing 30% of 
NaHCO3 / tartaric acid. 
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Table 1: polymeric formulation and operating parameters used for the manufacturing of extruded sheets and molded disks. 
Formulation Process conditions and performance 
Polymer 
Plasticizer 
(wt %) 
HME IM 
T1-T2-T3 -T4 
°C 
Screw rate 
rpm 
Torque* 
N m 
Processabilitya 
T1-T2-T3  
°C 
P1 
bar 
r1 
% 
P2 
bar 
r2 
% 
Processabilityb 
PEG 6000 - 65-60-60-55 50 1 - 65-60-55 15 20 10 15 - 
PEG 8000 - 65-65-60-55 50 1 - 65-60-55 15 20 10 15 - 
HPC PEG 1500 (10 %) 95-100-110-115 15 9 + 110-115-125 40 30 30 20 + 
HPMC PEG 400 (50 %) nd nd nd nd 130-140-150 30 50 20 40 -/+ 
KVA PEG 1500 (10 %) 140-150-155-145  30 5 -/+ 140-145-150 30 20 20 15 - 
KIR GLY (15 %) 150-140-150-140 25 10 + 130-135-150 50 40 30 20 + 
PVA GLY (20 %) 140-150-160-150 20 7 + 160-170-180 40 40 30 30 + 
Soluplus PEG 1500 (15 %) 90-95-100-120 40 5 -/+ 130-140-150 40 30 30 20 -/+ 
Eudragit E TEC (10 %) 145-155-160-150 60 10 -/+ 150-155-160 50 40 40 30 -/+ 
Starch W (15 %) / GLY (10 %) 75-90-110-95 55 7 -/+ 125-110-125 40 50 30 40 -/+ 
EXP 
W (20 %) / GLY (20 %) 
60-70-100-90 85 8 -/+ 90-125-120 30 50 20 45 -/+ 
EXPCLV 60-70-100-90 85 9 -/+ 90-125-130 30 50 20 45 -/+ 
VIV 60-70-100-90 85 10 -/+ 90-125-130 30 50 20 45 -/+ 
* maximum value obtained 
a HME processability: “-” no sheet obtained; “-/+” incomplete sheet with non-uniform thickness/extreme brittleness; “+” complete sheet with uniform thickness and suitable mechanical properties 
b IM processability: “-” broken/deformed disks; “-/+”not-automatically disks ejected/ extremely brittle; “+”automatically ejected disks with suitable mechanical properties 
“nd” not determined; the extrusion process failed 
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Table 2: mass loss parameters (CV < 5%), t10diss (time to 10% of mass loss in the dissolution apparatus) 
and t80-10diss (difference between the time to 80 and 10 % of mass loss in the dissolution apparatus), 
relevant to disk-shaped prototypes.  
Formulation HME disks IM disks 
Polymer 
Plasticizer  
(wt %) 
t10diss  
min 
t80-10diss 
min 
t10diss  
min 
t80-10diss 
min 
PEG 6000 - / / / / 
PEG 8000 - / / / / 
HPC PEG 1500 (10 %) < 5’ 39’ 24” < 5’ 21’ 03” 
HPMC PEG 400 (50 %) - - < 5’ 33’ 47” 
KVA PEG 1500 (10 %) nd nd / / 
KIR GLY (15 %) < 5’ 26’ 32” < 5 28’ 44” 
PVA GLY (20 %) 10’ 02” > 60 < 5  40’ 35” 
Soluplus PEG 1500 (15 %) 7’ 14” 46’ 50” 8’ 14” > 60’ 
Eudragit E TEC (10 %) nd nd < 5 * 26’ 44” * 
Starch W (15 %) / GLY (10 %) 39’ 20” > 80 10’ 07” > 90’ 
EXP 
W (20 %) / GLY (20 %) 
< 5’ 41’ 43” < 5’ 48’ 59” 
EXPCLV < 5’ 48’ 49” < 5’ 39’ 55” 
VIV < 5’ > 60’ < 5’ 34’ 28” 
“/” neither extruded sheets nor complete disks obtained 
“nd” not determined; no intact disks could be obtained by cutting 
* mass loss test was performed in 1N HCl solution 
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Table 3: composition and operative parameters used for the manufacturing of extruded and molded tablets based on EXPCLV and HPC. 
 
Formulation 
Process conditions 
HME IM 
Polymer 
Plasticizer 
(wt %) 
Drug 
(wt %) 
Adjuvant 
(30 %) 
T1-T2-T3 -T4 
°C 
Screw rate 
rpm 
Torque* 
N m 
T1-T2-T3 
°C 
P1 
bar 
r1 
% 
P2 
bar 
r2 
% 
1a 
HPC 
PEG 1500  
(10 %) 
- 
- 95-100-110-115 15 9 120-130-140 30 20 40 30 
1b AcdiSol 100-105-115-110 15 10 130-140-150 30 30 20 20 
1c L-HPC 100-105-115-110 15 10 130-145-150 30 30 20 20 
1d NaHCO3 100-105-115-115 15 12 130-135-130 40 35 30 25 
1e 
NaHCO3 / citric acid / 
CaCO3 
nd nd nd 130-135-130 50 40 40 30 
1f NaHCO3 / tartaric acid nd nd nd 130-135-130 40 40 30 30 
1g NaCl 95-100-110-115 15 18 130-135-130 40 40 30 30 
1h KIR 95-100-110-115 15 24 130-135-140 40 40 30 30 
1i 
Furosemide 
(20 %) 
- 90-100-115-115 60 14 100-120-130 30 50 20 40 
1l AcdiSol 90-100-115-115 60 19 100-120-130 30 40 20 30 
1m NaHCO3 / tartaric acid nd nd nd 130-135-130 40 40 30 30 
1n KIR 90-100-115-115 60 12 120-130-140 40 40 30 30 
1o NaCl 90-100-110-115 10 20 120-130-140 45 40 35 30 
2a 
EXPCLV 
W (20 %) /  
GLY (20 %) 
- 
- 60-70-100-90 65 9 100-130-140 50 20 40 30 
2b AcdiSol 60-70-110-90 40 20 90-130-120 40 40 30 30 
2c L-HPC 60-70-100-90 40 12 120-145-140 50 20 40 35 
2d NaHCO3 60-80-100-90 40 11 110-120-130 40 30 30 20 
2e 
NaHCO3 / citric acid 
CaCO3 
nd nd nd 110-120-130 40 40 30 30 
2f NaHCO3 / tartaric acid 60-80-100-90 40 12 110-120-130 40 40 30 30 
2g NaCl 60-80-100-90 40 8 110-120-130 40 40 30 30 
2h KIR 60-90-110-90 40 8 110-120-130 40 40 30 30 
2i 
Furosemide 
(20 %) 
- 60-65-85-80 50 10 100-110-115 30 30 20 20 
2l AcdiSol 80-90-100-95 30 30 100-110-115 30 30 20 20 
2m NaHCO3 / tartaric acid 80-90-100-95 30 25 100-110-115 40 40 30 30 
2n KIR 60-80-100-80 40 12 120-115-120 40 40 30 30 
2o NaCl 60-80-100-80 40 14 110-115-120 50 40 40 30 
* maximum value obtained 
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Table 4: percentage of furosemide dissolved after 20 and 60 min (%20min and %60min, respectively) from 
HPC- and EXPCLV-based tablets containing dissolution/disintegration adjuvants. 
 Formulation HME IM 
Polymer 
Plasticizer 
(wt%)  
Drug 
(20 %) 
Adjuvant 
(30 %) 
%20min (cv) %60min (cv) %20min (cv) %60min (cv) 
1a 
HPC 
PEG 1500 
(10%) 
Furosemide 
- 7.02 (11.05) 28.93 (6.42) 1.47 (3.15) 4.47 (6.44) 
1b AcdiSol  6.56 (9.10) 24.25 (10.46) 6.13 (9.1) 18.37 (1.41) 
1e 
NaHCO3 / 
tartaric acid  
- - 12.95 (7.92) 39.13 (3.05) 
1f KIR 10.04 (7.04) 34.65 (4.29) 2.88 (0.33) 22.03 (12.86) 
2a 
EXPCLV 
W (20 %) / 
GLY (20 %) 
Furosemide 
- 32.45 (1.10) 86.76 (2.96) 23.09 (9.70) 65.64 (2.40) 
2b AcdiSol  6.97 (14.36) 28.22 (22.62) 5.84 (9.44) 17.26 (6.23) 
2e 
NaHCO3 / 
tartaric acid 
27.93 (0.86) 74.93 (0.46) 51.58 (11.25) 99.8 (4.57) 
2f KIR 45.97 (7.32) 100.00 (3.00) 38.77 (9.65) 100.00 (7.90) 
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X-ray profiles of powdered Explotab® CLV and polymer-based sheets immediately after extrusion and after 
6 months storage.  
80x54mm (300 x 300 DPI)  
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mass loss profiles of the HPC- and EXPCLV-based tablets performed in the dissolution (a) or disintegration 
(b) equipment.  
80x98mm (300 x 300 DPI)  
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Digital photographs and photomicrographs of molded placebo tablets based on HPC and EXPCLV, before and 
after exposure to the aqueous medium. Digital photographs are referred to units tested in the dissolution 
apparatus.  
160x95mm (300 x 300 DPI)  
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Dissolution profiles of HPC- and EXPCLV-based tablets containing furosemide.  
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Photomicrographs of (a) HPC- and (b) EXPCLV-based placebo molded tablets containing 30% of NaHCO3 / 
tartaric acid.  
80x36mm (300 x 300 DPI)  
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